High Quality Furagin CAS NO (1672-88-4) Available For Sale

Furagin (1672-88-4)

1. Chemical Identity: Furagin is a synthetic nitrofuran derivative with the chemical formula C8H6N4O5 and the CAS number 1672-88-4. It is characterized by its nitrofuran core, which consists of a furan ring with a nitro group attached, and additional functional groups contributing to its pharmacological properties.

2. Synthesis: Furagin is synthesized through the reaction of 5-nitro-2-furaldehyde with urea or semicarbazide under controlled conditions. The synthetic route may involve multiple steps, including condensation, cyclization, and nitration reactions, to yield the final product, furagin.

3. Pharmacological Activity: Furagin exhibits antibacterial activity against a broad spectrum of Gram-positive and Gram-negative bacteria, including Escherichia coli, Staphylococcus aureus, and Proteus species. It functions by inhibiting bacterial DNA synthesis and disrupting essential cellular processes, ultimately leading to bacterial cell death.

4. Therapeutic Uses: Furagin is primarily used for the treatment of urinary tract infections (UTIs), including cystitis and pyelonephritis, caused by susceptible bacterial strains. It is effective in eradicating bacteria from the urinary tract and alleviating symptoms associated with UTIs.

5. Administration: Furagin is typically administered orally in the form of tablets or capsules. The dosage and duration of treatment may vary depending on the severity of the infection, the patient's age and weight, and the specific bacterial strain causing the UTI.

6. Safety Profile: Furagin is generally well-tolerated, with adverse effects being relatively uncommon. However, it may cause gastrointestinal disturbances such as nausea, vomiting, and diarrhea in some individuals. Allergic reactions are rare but can occur in sensitive individuals.

7. Resistance and Sensitivity: Prolonged or indiscriminate use of furagin can contribute to the development of bacterial resistance. Therefore, it is essential to use this medication judiciously and according to prescribed guidelines to minimize the risk of resistance emergence and preserve its effectiveness.

8. Pediatric and Special Populations: Furagin is suitable for use in pediatric patients, although dosing adjustments may be necessary based on the child's age and weight. Special caution is warranted in pregnant and breastfeeding women, and the medication should be used only if the potential benefits outweigh the risks.

9. Regulatory Approval and Availability: Furagin may be available under different brand names in various countries, and its availability may vary depending on local regulatory approvals and marketing authorizations. It is typically obtained through prescription from a qualified healthcare professional.

10. Future Perspectives: Continued research on furagin and its derivatives may focus on optimizing its pharmacokinetic properties, improving its spectrum of activity, and minimizing potential adverse effects. Additionally, efforts to combat bacterial resistance and ensure appropriate antibiotic stewardship are crucial for preserving the efficacy of furagin and other antibacterial agents in clinical practice.